Professor Martin Wehling accepted our Invitation as Scientific Advisory Board for AcaHealth company
He had been invited as Director of discovery medicine /experimental medicine at AstraZeneca R&D, Mölndal.
Professor Wehling mentioned it is good thing to line up our interests, and wish all of us do the best in continuing with this exciting project. when he viewed our slides and scientific records, he strongly believe in plant derived principles like EH-201, if properly tested and developed, can fully support his assumption that we are exactly on this tract.
Professor M.Wehling
Director Clinical Pharmacology, Faculty of Medicine Mannheim. Ruprecht-Karls-University of Heidelberg,
Director of discovery medicine/experimental medicine at AstraZeneca R&D, Mölndal.
Main tasks: translational medicine, linking pre-clinical and clinical activities across borders, development of efficacy and safety biomarker and valid proof-of-principle concepts, mainly in cardiovascular medicine, with some attention to gastrointestinal issues.
51 phase I-IV trials, mostly in the fields of hypertension, heart failure and endocrine disorders, mainly in collaboration with 15+ drug companies.
Publications: From 1980 to present approximately 250 PubMed citations, 4 books.